首页> 外文期刊>Journal of cardiovascular magnetic resonance : >Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance
【24h】

Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance

机译:高脂高蔗糖饮食小鼠模型中心脏代谢变化的时程和使用多峰心血管磁共振的GLP-1类似物治疗后的改善

获取原文
获取外文期刊封面目录资料

摘要

BackgroundCardiovascular complications of obesity and diabetes are major health problems. Assessing their development, their link with ectopic fat deposition and their flexibility with therapeutic intervention is essential. The aim of this study was to longitudinally investigate cardiac alterations and ectopic fat accumulation associated with diet-induced obesity using multimodal cardiovascular magnetic resonance (CMR) in mice. The second objective was to monitor cardiac response to exendin-4 (GLP-1 receptor agonist).MethodsMale C57BL6R mice subjected to a high fat (35 %) high sucrose (34 %) (HFHSD) or a standard diet (SD) during 4 months were explored every month with multimodal CMR to determine hepatic and myocardial triglyceride content (HTGC, MTGC) using proton MR spectroscopy, cardiac function with cine cardiac MR (CMR) and myocardial perfusion with arterial spin labeling CMR. Furthermore, mice treated with exendin-4 (30 μg/kg SC BID) after 4 months of diet were explored before and 14 days post-treatment with multimodal CMR.ResultsHFHSD mice became significantly heavier (+33 %) and displayed glucose homeostasis impairment (1-month) as compared to SD mice, and developed early increase in HTGC (1 month, +59 %) and MTGC (2-month, +63 %). After 3 months, HFHSD mice developed cardiac dysfunction with significantly higher diastolic septum wall thickness (sWtnD) (1.28 ± 0.03 mm vs. 1.12 ± 0.03 mm) and lower cardiac index (0.45 ± 0.06 mL/min/g vs. 0.68 ± 0.07 mL/min/g, p = 0.02) compared to SD mice. A significantly lower cardiac perfusion was also observed (4 months:7.5 ± 0.8 mL/g/min vs. 10.0 ± 0.7 mL/g/min, p = 0.03). Cardiac function at 4 months was negatively correlated to both HTGC and MTGC (p < 0.05). 14-day treatment with Exendin-4 (Ex-4) dramatically reversed all these alterations in comparison with placebo-treated HFHSD. Ex-4 diminished myocardial triglyceride content (?57.8 ± 4.1 %), improved cardiac index (+38.9 ± 10.9 %) and restored myocardial perfusion (+52.8 ± 16.4 %) under isoflurane anesthesia. Interestingly, increased wall thickness and hepatic steatosis reductions were independent of weight loss and glycemia decrease in multivariate analysis (p < 0.05).ConclusionCMR longitudinal follow-up of cardiac consequences of obesity and diabetes showed early accumulation of ectopic fat in mice before the occurrence of microvascular and contractile dysfunction. This study also supports a cardioprotective effect of glucagon-like peptide-1 receptor agonist.Electronic supplementary materialThe online version of this article (doi:10.1186/s12968-015-0198-x) contains supplementary material, which is available to authorized users.
机译:背景技术肥胖和糖尿病的心血管并发症是主要的健康问题。评估它们的发育,与异位脂肪沉积的联系以及在治疗干预中的灵活性至关重要。这项研究的目的是使用多模式心血管磁共振(CMR)纵向研究与饮食引起的肥胖有关的心脏改变和异位脂肪蓄积。第二个目的是监测对exendin-4(GLP-1受体激动剂)的心脏反应。方法雄性C57BL6R小鼠在4天内接受了高脂肪(35%)高蔗糖(34%)(HFHSD)或标准饮食(SD)的治疗每月使用多峰CMR探索几个月,以使用质子MR光谱,心功能与电影心脏MR(CMR)以及心肌灌注与动脉自旋标记CMR来确定肝和心肌甘油三酯含量(HTGC,MTGC)。此外,在多模式CMR治疗前和治疗后14天,对饮食4个月后用exendin-4(30μg/ kg SC BID)处理的小鼠进行了研究,结果HFHSD小鼠变得更重(+33%),并表现出葡萄糖体内稳态损害( 1个月),与SD小鼠相比,HTGC(1个月,+ 59%)和MTGC(2个月,+ 63%)出现了早期升高。 3个月后,HFHSD小鼠出现心脏功能障碍,舒张期间隔壁厚度(sWtnD)明显升高(1.28±0.03 mm对1.12±0.03 mm),心脏指数降低(0.45±0.06 mL / min / g对0.68±0.07 mL / min / g,p = 0.02)。还观察到明显较低的心脏灌注(4个月:7.5±0.8 mL / g / min与10.0±0.7 mL / g / min,p = 0.03)。 4个月时的心脏功能与HTGC和MTGC均呈负相关(p <0.05)。与安慰剂治疗的HFHSD相比,用Exendin-4(Ex-4)治疗14天可显着逆转所有这些变化。 Ex-4减少了异氟烷麻醉下的心肌甘油三酯含量(?57.8±4.1%),改善了心脏指数(+38.9±10.9%),恢复了心肌灌注(+52.8±16.4%)。有趣的是,在多变量分析中,壁厚的增加和肝脂肪变性的减少与体重减轻和血糖降低无关(p <0.05)。结论肥胖和糖尿病的心脏后果的CMR纵向随访显示,在小鼠出现异位脂肪之前,其早期积累了异位脂肪微血管和收缩功能障碍。这项研究还支持胰高血糖素样肽1受体激动剂的心脏保护作用。电子补充材料本文的在线版本(doi:10.1186 / s12968-015-0198-x)包含补充材料,授权用户可以使用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号